CORC

在结果中检索

CORC

浏览/检索结果: 共81条，第1-10条 帮助

已选(0)清除 条数/页：   排序方式：
Ship Target Detection Algorithm Based on Improved Faster R-CNN 期刊论文
ELECTRONICS, 2019, 卷号: 8, 期号: 9, 页码: 19
作者:  Qi, Liang;  Li, Bangyu;  Chen, Liankai;  Wang, Wei;  Dong, Liang
收藏  |  浏览/下载：65/0  |  提交时间：2019/12/16
LncRNA CRNDE promotes hepatocellular carcinoma cell proliferation, invasion, and migration through regulating miR-203/BCAT1 axis 期刊论文
JOURNAL OF CELLULAR PHYSIOLOGY, 2019, 卷号: 234, 期号: 5
作者:  Ji, Degang;  Jiang, Chengwei;  Zhang, Lirong;  Liang, Na;  Jiang, Tiechao
收藏  |  浏览/下载：31/0  |  提交时间：2019/12/05
All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 期刊论文
JOURNAL OF HEPATOLOGY, 2019, 卷号: 70
作者:  Gong, Guozhong;  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun
收藏  |  浏览/下载：57/0  |  提交时间：2019/12/05
Long-term efficacy and safety of tenofovir disoproxil fumarate in Chinese patients with chronic hepatitis B: 5-year results 期刊论文
HEPATOLOGY INTERNATIONAL, 2019, 卷号: 13, 期号: 3
作者:  Liang, Xieer;  Gao, Zhiliang;  Xie, Qing;  Zhang, Jiming;  Sheng, Jifang
收藏  |  浏览/下载：45/0  |  提交时间：2019/12/05
All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Ji-Fang
收藏  |  浏览/下载：45/0  |  提交时间：2019/12/05
Statistical Evaluation of Radiofrequency Exposure during Magnetic Resonant Imaging: Application of Whole-Body Individual Human Model and Body Motion in the Coil 期刊论文
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2019, 卷号: 16
作者:  Liu, Wenli;  Wang, Hongkai;  Zhang, Pu;  Li, Chengwei;  Sun, Jie
收藏  |  浏览/下载：29/0  |  提交时间：2019/12/02
THE EFFICACY AND SAFETY OF RAVIDASVIR COMBINED WITH DANOPREVIR IN THE 12-WEEK ORAL REGIMEN FOR TREATMENT-NAIVE HCV GENOTYPE 1 ADULT PATIENTS WITHOUT CIRRHOSIS IN CHINA: PHASE II/III CLINICAL TRIAL 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Zheng, Sujun;  Guan, Yujuan;  Sheng, Jifang
收藏  |  浏览/下载：35/0  |  提交时间：2019/12/05
All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Ji-Fang
收藏  |  浏览/下载：36/0  |  提交时间：2019/12/05
THE EFFICACY AND SAFETY OF RAVIDASVIR COMBINED WITH DANOPREVIR IN THE 12-WEEK ORAL REGIMEN FOR TREATMENT-NAIVE HCV GENOTYPE 1 ADULT PATIENTS WITHOUT CIRRHOSIS IN CHINA: PHASE II/III CLINICAL TRIAL 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Zheng, Sujun;  Guan, Yujuan;  Sheng, Jifang
收藏  |  浏览/下载：32/0  |  提交时间：2019/12/05
All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Ji-Fang
收藏  |  浏览/下载：29/0  |  提交时间：2019/12/05

©版权所有 ©2017 CSpace - Powered by CSpace